Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

被引:2
|
作者
Sun, Dongxu [1 ]
Rubio-Aparicio, Debora [1 ]
Nelson, Kirk [1 ]
Dudley, Michael N. [1 ]
Lomovskaya, Olga [1 ]
机构
[1] Med Co, San Diego, CA 07054 USA
关键词
vaborbactam; Klebsiella pneumoniae carbapenemases; KPC; resistance development; single-step mutants; BETA-LACTAMASE INHIBITOR; SEQUENCE TYPE 258; CARBAPENEM RESISTANCE; CEFTAZIDIME-AVIBACTAM; ENTEROBACTERIACEAE; RPX7009; SUSCEPTIBILITY; GENE; MUTATIONS; STRAINS;
D O I
10.1128/AAC.01694-17
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Klebsiella pneumoniae carbapenemases (KPC). It has been developed in combination with meropenem. The objective of these studies was to identify the concentrations of both agents associated with the selection or prevention of single-step mutations leading to reduced sensitivity to the combination and to characterize the selected mutations. Eighteen strains of KPC-producing Klebsiella pneumoniae with various degrees of sensitivity to meropenem (MICs, 8 to 512 mu g/ml) and meropenem-vaborbactam (MICs, <= 0.06 to 32 mu g/ml) and preexisting resistance mechanisms were selected from a worldwide collection of isolates recovered from surveillance studies, emphasizing strains for which MICs were in the upper range of the meropenem-vaborbactam MIC distribution. Meropenem and vabor-bactam at 8 mu g/ml each suppressed the drug resistance mutation frequency to <1 X 10(-8) in 77.8% (14/18) of strains, and all strains were inhibited when the meropenem concentration was increased to 16 mu g/ml. Mutants selected at lower drug concentrations showed phenotypes associated with previously described carbapenem resistance mechanisms, including ompK36 inactivation in mutants selected from OmpK36-proficient strains and an increased bla(KPC) gene copy number in strains with partially functional ompK36. No mutations in the coding region of bla(KPC) were identified. These data indicate that the selection of mutants with reduced sensitivity to meropenem-vaborbactam from KPC-producing Klebsiella pneumoniae strains is associated with previously described mechanisms involving porin mutations and the increase in the bla(KPC) gene copy number and not changes in the KPC enzyme and can be prevented by the drug concentrations achieved with optimal dosing of the combination.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Diversity, virulence, and antimicrobial resistance of the KPC-producing Klebsiella pneumoniae ST307 clone
    Villa, Laura
    Feudi, Claudia
    Fortini, Daniela
    Brisse, Sylvain
    Passet, Virginie
    Bonura, Celestino
    Endimiani, Andrea
    Mammina, Caterina
    Maria Ocampo, Ana
    Natalia Jimenez, Judy
    Doumith, Michel
    Woodford, Neil
    Hopkins, Katie
    Carattoli, Alessandra
    MICROBIAL GENOMICS, 2017, 3 (04):
  • [32] Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae
    Guo, Yingyi
    Liu, Ningjing
    Lin, Zhiwei
    Ba, Xiaoliang
    Zhuo, Chuyue
    Li, Feifeng
    Wang, Jiong
    Li, Yitan
    Yao, Likang
    Liu, Baomo
    Xiao, Shunian
    Jiang, Ying
    Zhuo, Chao
    EMERGING MICROBES & INFECTIONS, 2021, 10 (01) : 2042 - 2051
  • [33] Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection
    Sheng Bi
    Xin Yao
    Cheng Huang
    Xia Zheng
    Tianming Xuan
    Jifang Sheng
    Kaijin Xu
    Beiwen Zheng
    Qing Yang
    Infection, 2019, 47 : 497 - 500
  • [34] Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection
    Bi, Sheng
    Yao, Xin
    Huang, Cheng
    Zheng, Xia
    Xuan, Tianming
    Sheng, Jifang
    Xu, Kaijin
    Zheng, Beiwen
    Yang, Qing
    INFECTION, 2019, 47 (03) : 497 - 500
  • [35] Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate
    Gaibani, Paolo
    Bianco, Gabriele
    Amadesi, Stefano
    Boattini, Matteo
    Ambretti, Simone
    Costa, Cristina
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (05)
  • [36] In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-β-lactamase-producing Klebsiella pneumoniae
    Cienfuegos-Gallet, Astrid V.
    Shashkina, Elena
    Chu, Tingyu
    Zhu, Zhichen
    Wang, Bingjie
    Kreiswirth, Barry N.
    Chen, Liang
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (04)
  • [37] Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
    Campogiani, Laura
    Vitale, Pietro
    Lodi, Alessandra
    Imeneo, Alessandra
    Fontana, Carla
    D'Agostini, Cartesio
    Compagno, Mirko
    Coppola, Luigi
    Spalliera, Ilaria
    Malagnino, Vincenzo
    Teti, Elisabetta
    Iannetta, Marco
    Andreoni, Massimo
    Sarmati, Loredana
    ANTIBIOTICS-BASEL, 2023, 12 (05):
  • [38] Novel patterns in the molecular epidemiology of KPC-producing Klebsiella pneumoniae in Tucuman, Argentina
    Jure, Maria A.
    Castillo, Marta E.
    Musa, Humberto E.
    Lopez, Carolina G.
    Caceres, Mariel A.
    Mochi, Silvana D.
    Bousquet, Aurore A.
    Genel, Nathalie A.
    Arlet, Guillaume A.
    Decre, Dominique C.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 19 : 183 - 187
  • [39] KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6′)-Ib Exhibit Intermediate Resistance to Amikacin
    Bremmer, Derek N.
    Clancy, Cornelius J.
    Press, Ellen G.
    Almaghrabi, Reem
    Chen, Liang
    Doi, Yohei
    Hong Nguyen
    Shields, Ryan K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (12) : 7597 - 7600
  • [40] Meropenem-Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature
    Rezzonico, Leonardo Francesco
    Peracchi, Francesco
    Vecchi, Marta
    Bassi, Gabriele
    Merli, Marco
    Bana, Nicholas Brian
    Travi, Giovanna
    Crippa, Fulvio
    Puoti, Massimo
    ANTIBIOTICS-BASEL, 2024, 13 (04):